Novartis Says Top Drugs Should Fuel Sales Growth Through 2026
December 02 2021 - 2:22AM
Dow Jones News
By Olivia Bugault
Novartis AG said Thursday ahead of its research-and-development
day starting later today that it expects sales to keep growing in
the mid-term mainly thanks to its main in-market growth drivers,
while several new assets could be approved by 2026.
The Swiss pharma giant said that sales should continue to rise
at a compound annual growth rate of at least 4% through 2026,
driven by multi-billion dollar sales from its medicines Cosentyx,
Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio.
"Up to 20 new assets with significant sales potential could be
approved by 2026, which will fuel the next phase of growth and
address major unmet needs," Novartis's Chief Executive Vas
Narasimhan said.
Novartis also said that Cosentyx, its largest drug by sales, met
primary efficacy endpoints in two phase 3 studies called Sunrise
and Sunshine in which patients are treated for moderate to severe
hidradenitis suppurativa--a chronic skin disease.
Write to Olivia Bugault at olivia.bugault@wsj.com
(END) Dow Jones Newswires
December 02, 2021 02:07 ET (07:07 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2023 to Sep 2024